Context: Previous studies have implicated growth hormone (GH) in the progression of several cancers, including breast, colorectal, and pancreatic. A mechanism by which GH may play this role in cancer is through the induction of the epithelial-to-mesenchymal transition (EMT). During the EMT process, epithelial cells lose their defining phenotypes, causing loss of cellular adhesion and increased cell migration. This review aims to carefully summarize the previous two decades of research that points to GH as an initiator of EMT, in both cancerous and noncancerous tissues.
pithelial-to-mesenchymal transition (EMT) is a biological process induced in epithelial cells during embryogenesis or under stress, as would occur during tissue repair or carcinogenesis. The ability for cells to transition from one type to another was first noted in the early 1900s, but not described in detail until 1984 (1) (2) (3) . Several reviews concerning the pathophysiology of EMT have been written, including an excellent review by Tiery in 2002 (4) , with more recent reviews by Kalluri and Weinberg (5), Foroni et al. (6) , Tsai and Yang (7) , and Lamouille et al. (8) .
The most recognized role for EMT is in cancer as a driver of the transition from a tumor with well-defined borders to an invasive, metastatic cancer. Current research has implicated EMT in the development of chemotherapeutic resistance, as reported for crizotinib and gefitinib resistance in lung cancer (9) (10) (11) . EMT has also been implicated in other noncancerous disorders, specifically fibrotic renal and lung diseases (12, 13) . This type of EMT is classified as type 2, which occurs during wound healing and tissue repair. Type 1 EMT is associated with normal embryonic development, whereas type 3 occurs in cancerous cells (5) .
The ability for EMT to occur in a specific cell, thus potentiating a more invasive cancer or enhanced disease model, rests upon the principle that certain cells of the epithelial origin are more plastic than others and can be coerced to undergo EMT (7, 14) . This transition is initiated by factors secreted from the affected cell and/or its surrounding environment, most notably transforming growth factor-b (TGF-b), hepatocyte growth factor, insulinlike growth factor (IGF), epidermal growth factor, WNT family proteins, and NOTCH receptor ligands. Activation of their cognate receptors regulates downstream transcription factors such as ZEB1, ZEB2, TWIST, SRC, RAS/RAC, BCL9-2, SMAD2, SNAIL1, and SNAIL2 (15) .
The role of messenger RNA (mRNA) processing via microRNAs (miRNAs) and alternative splicing in the EMT process is important. The miR-200 family is heavily implicated in EMT suppression, performing this function by binding ZEB1 and ZEB2 mRNAs to inhibit translation (16) . Alternative splicing via regulation of ESRP1 and ESRP2 also plays a critical role, specifically via the targeting of ZEB proteins (17) . The result of these processes is the regulation of key genes and proteins found in cell junctions or basement membrane adhesions, such as focal adhesions and hemidesmosomes, which dictates the epithelial or mesenchymal phenotype (Fig. 1) .
Hallmarks of EMT include increases in fibroblastinteracting and mesenchymal molecules like N-cadherin and vimentin, with concurrent loss of epithelial marker E-cadherin and subsequent nuclear localization of b-catenin (18) . E-cadherin is an adaptor protein that anchors cells to the extracellular matrix (ECM) via connections with actin. These connections are stabilized by undercoat proteins, including a-, b-, and g-catenins and PP120, that connect adherens junctions with intracellular actin filaments. When E-cadherin is disrupted or its production decreased, unbound b-catenin travels to the nucleus and acts as a transcription factor, increasing activity of the WNT pathway (19) . E-cadherin is significantly decreased in human melanoma, hepatocellular carcinoma, and pancreatic adenocarcinoma, and the WNT pathway is known to be induced in various cancers (20) (21) (22) (23) (24) (25) . Many of the above-mentioned factors (ZEB, SMAD, and SNAIL, etc.) decrease E-cadherin expression by protein degradation, promoter methylation, and/or transcriptional repression (26) (27) (28) . EMT processes are also encouraged by specific changes in the microenvironment surrounding the cell. This environment, which includes fibroblasts and immune cell infiltrates, can cause increases in ECM remodeling by secretion of proteins like matrix metalloproteinases (MMPs) and growth factors (29, 30) .
Recent studies suggest that growth hormone (GH) can directly induce EMT, both in cancerous and noncancerous epithelial cells (Table 1) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) . The following review focuses on those studies, aiming to summarize the current mechanistic theory of GH-induced EMT.
GH-induced EMT in cancer models
GH affects most tissues in the body, most notably bone and cartilage, skeletal muscle, kidney, adipose tissue, and liver. Some of its effects include the stimulation of lipolysis, gluconeogenesis, and bone remodeling. Most tissues respond to GH by producing IGF1; the primary source of IGF1 is the liver. GH acts on its receptor, the GHR, to induce phosphorylation of several intracellular second messenger molecules, including JAK2 and STAT5, which regulate downstream gene expression. In several animal models (from worms to mice), the reduction of GH action is associated with increased health and lifespan, including decreased cancer incidence (46) (47) (48) .
The ability of GH to exacerbate cancer progression has been hotly debated over the past two decades. Patients with Laron syndrome, a disorder caused by lossof-function mutations in the GHR, have remarkably low incidences of cancer, in agreement with studies of GHR 2/2 mice (49, 50) . A recent 2016 report of 200 individuals with acromegaly found malignant neoplasms to be more common in this population (51), a finding supported by research performed in the 1980s (52, 53) . Other studies have found increased risks of colorectal carcinoma in acromegalics and little to no increased risk in patients receiving GH replacement therapy (54) . Female transgenic mice that express the human GH (hGH) gene also have high incidences of malignant mammary adenocarcinoma (55) . It has since been proposed that acromegaly is most frequently associated with thyroid, breast, and colon cancers, in that order (56, 57) . EMT associated with GH has been most reported in breast cancer (58) .
GH in breast cancer EMT
Numerous studies have provided evidence for variations in serum levels of GH or IGF1 in patients with breast cancer (53, (59) (60) (61) (62) . At the cellular level, hGH mRNA has been detected by reverse transcription polymerase chain reaction in RNA extracted from both normal and diseased human mammary tissue. This expression is mostly restricted to epithelium and myoepithelium in normal tissue, with notable spreading to the stroma and overall increased expression in the diseased mammary gland (63, 64) . Research indicates that tamoxifen, an antineoplastic E2 receptor modulator, suppresses pituitary GH output and IGF1 levels likely by modulation of GH-releasing hormone (GHRH) release, further supporting a procancer role for GH in progression of mammary cancer (65) (66) (67) . An early study to determine the effect of hGH on breast cancer proliferation documented a twofold increase in tumor proliferation activity in response to recombinant human GH injection 2 days prior to chemotherapy (68) . A detailed history of experiments supporting this relationship and the role of GH in normal and diseased breast development can be found in several excellent reviews (69) (70) (71) .
Much of the research concerning GH-induced EMT in breast cancer has been conducted in the laboratory of Peter Lobie using MCF7 cells, a line of human mammary adenocarcinoma established in the 1970s (31-39, 41, 44, 69, 72-75) . Commonly used experimental mutants of this line include MCF7-hGH and MCF7-MUT cells, which are produced by constitutive activation or mutation of the hGH gene, respectively. In MCF7-hGH cells, hGH expression is under control of the metallothionein Figure 1 . Molecular and cellular model of EMT, in which several potential growth factors [e.g., TGF-b and epidermal growth factor (EGF)] act on their cognate receptors to activate downstream intracellular signaling molecules (e.g., ZEB2 and SMAD). These factors result in the regulation of genes involved in a shift from the epithelial phenotype to the mesenchymal phenotype, including upregulation of vimentin with decreased E-cadherin and loss of junctional proteins. b, b-catenin; BP, bullous pemphigoid proteins; DSH, disheveled; FAK, focal adhesion kinase; FGF, fibroblast growth factor; FZD, frizzled; HGF, hepatocyte growth factor; P, paxillin; PDGF, platelet-derived growth factor; RAS, Ras family proteins (rat sarcoma); RTK, receptor tyrosine kinase; V, vinculin; WNT, Wnt family proteins (wingless-related integration); ZO, zonula occludens.
1a promoter. The MCF7-MUT line, commonly used as controls, is created by an ATG to TTG mutation in the start codon of hGH. An overview of the cellular mechanisms implicated in GH-induced EMT in MCF7 cell lines is found in Fig. 2 .
It is important to note that MCF7 cell lines are most relevant for the study of autocrine/paracrine GH action, which has distinct effects from the systemic endocrine actions associated with the pituitary GH/IGF1 axis. For example, autocrine/paracrine and not exogenous hGH has been shown to downregulate the apoptotic gene placental TGF-b (PTGF-b) and upregulate TGF-b expression in MCF7 cells (33, 34) . Gene-expression studies of these cells identified 305 genes exclusively regulated by autocrine/paracrine hGH, with 167 genes regulated by both autocrine/paracrine hGH and exogenous hGH exposure (36) . Perhaps most strikingly, autocrine/paracrine hGH, not exogenous hGH, has been associated with increased cell growth in mammary epithelial cells (37) . These distinctions are not restricted to mammary carcinomas, as increased GH transcription and increased nuclear GHR expression has been correlated with enhanced invasiveness in several cancer types both in vitro and in vivo, including endometrial, colorectal, and hepatocellular carcinoma and melanoma (72, (76) (77) (78) (79) (80) (81) .
The distinct effects of autocrine/paracrine GH and systemic endocrine GH require careful examination, particularly in light of similar procancerous effects of IGF1. Constitutive activation of the IGF1 receptor in immortalized mammary cells is known to induce markers of EMT, including increased SNAIL and subsequent downregulation of E-cadherin (9). This activity is associated with increases in phosphoinositide 3-kinase (PI3K)/AKT pathway activation and a change to the typical EMT phenotype (82) . By phosphorylation of AKT, IGF1 can induce mucin 1, resulting in nuclear translocation of b-catenin (83). Given these findings, EMT mediated by GH in mammary tissue can potentially occur in three ways: (1) by endocrine GH action via binding to GHRs on the cell surface, (2) through increased IGF1 production in response to circulating GH, and (3) by increased autocrine/ paracrine GH activity on nuclear and/or transmembrane GH receptors, occurring through constitutive activation or overexpression of GH. Notably, forced GH expression in MCF7 cells is not associated with increases in IGF1 expression. Thus, in the MCF7 model of breast cancer, GH-induced IGF1 production is not likely to play a substantial role in overall GH-induced EMT (31) . Although, as mentioned previously, there have been documented increases in global GH/IGF1 activity in patients with breast cancer, it is the autocrine/paracrine condition that is most relevant in MCF7-hGH studies.
In 1999, Kaulsay et al. (31) demonstrated that MCF7-hGH cells secrete concentrations of autocrine/ paracrine hGH in the range of 100 pM, compared with physiologic and common experimental exogenous concentrations of 0.05 to 0.227 nM and 2.27 nM (1-5 ng/mL and ;50 ng/mL), respectively. Despite such small concentrations, autocrine/paracrine hGH stimulated greater increases in cell number than exogenously supplied hGH, likely due to activity on nuclear GHRs (84) . Such minute concentrations also stimulated marked IGF1-independent proliferation in serum-free and serum-rich conditions due to increased mitogenesis and decreased apoptosis. These effects were shown to be abrogated by inhibition of the p42/44 or p38 mitogen-activated protein kinase (MAPK) pathways (31) . The p38 MAPK-dependent transcription factor CAAT/ enhancer-binding protein-homologous protein (CHOP) was later identified as a mediator of autocrine/paracrine GH-dependent decreases in MCF7 apoptosis (33) .
Constitutive expression of hGH in mammary carcinoma has also been associated with a more invasive phenotype. In 2000, Kaulsay et al. (32) found MCF7-hGH and immortalized MCF10A-hGH cells spread more rapidly and anchor more quickly than MCF-MUT cells in collagen and three-dimensional matrices. This effect occurred in a JAK2-dependent manner, as the JAK2 inhibitor AG490 prevented hGH-induced cell spreading (32, 37) . A later study demonstrated that hGH uses homeobox A1 (HOXA1) to govern transcription of key genes involved in this invasive process, including cMYC, cyclin D1, and BCL-2 (73). In 2015, Chen et al. (74) found that forced expression of hGH stimulates tumor initiation capacity and enhances MDA-MB-453 cell metastasis in immunodeficient nude mice. However, the mechanisms of EMT regulation by autocrine/paracrine hGH in these tumors were not studied (74) .
Plakoglobin, also known as g-catenin, is a homolog of b-catenin. Both molecules perform the same function of stabilizing E-cadherin in epithelial adherens junctions. When E-cadherin is lost, these catenins can be translocated to the nucleus, where they act as WNT pathway transcription factors (85, 86) . In 2004, Mukhina et al. (35) found significantly decreased plakoglobin expression in MCF7-hGH cells. This decrease stimulated a more invasive phenotype, as evidenced by increased migration in wound healing and Transwell assays and cytoplasmic relocalization of E-cadherin. Inhibiting the SRC kinase family with PP2 restored plakoglobin expression and returned the cell to a less-invasive phenotype. The MMP2 and MMP9 inhibitor GM6001 was also able to restore the less-invasive phenotype. Interestingly, JAK2 inhibition with AG490 had no effect on plakoglobin expression, but did have an effect on JAK/STAT-mediated transcription, leading to the conclusion that hGH inhibition of plakoglobin is likely c-SRC and MMP mediated (35) .
A study performed in 2008 (39) determined that hGH regulates plakoglobin gene expression by stimulating expression of methyltransferases DNMT3A and DNMT3B in both an SRC-and JAK2-dependent manner. The increase in DNMT3A/B activity was accomplished primarily through JAK2 and SRC kinases acting to increase transcription, with JAK2 regulating DNMT3B transcription to a more substantial degree than DNMT3A. Concomitant increases, but not individual increases, in both DNMT3A and DNMT3B expression caused increased methylation of CpG islands present in exon 1 of the plakoglobin gene, thus decreasing transcription. Concomitant removal of both DNMT3A and DNMT3B with small interfering RNAs (siRNAs) restored the cell to a noninvasive phenotype (39) .
The degree to which JAK2 vs SRC is responsible for GH-induced EMT via plakoglobin repression remains unclear. The 2004 study (35) indicated that JAK2 inhibition with AG490 did not restore plakoglobin expression. However, the 2008 study (39) indicated JAK2 as responsible for increased DNMT3A and DNMT3B gene expression. Removal of these DNMTs by siRNA restored plakoglobin expression and the less-invasive phenotype. However, it was unclear in this study whether JAK2 inhibition alone restored the less-invasive phenotype. Neither study directly mentioned the effect of JAK2 inhibition on the phenotype of MCF7 cells. The question remains: does JAK2 inhibition restore the less-invasive phenotype by restoring plakoglobin expression?
Most recently, MCF7-hGH cells were shown to have increased telomerase activity in a JAK2-dependent manner. By first increasing a-CP1, a protein that binds to CU-rich cis-regulatory elements in the 3 0 -untranslated region, hGH increases the stability of human telomerase reverse transcriptase mRNA, thus increasing the activity of the downstream telomerase complex (38) .
hGH expression in MCF7 cells is also known to stimulate expression of miRNA cluster 96-182-183 in seven metastatic cell lines. This cluster is highly associated with breast cancer and increased tumor invasiveness (87) . hGH-induced upregulation of miRNA 96-182-183 in MCF7-hGH cells induced a mesenchymal phenotype with lower E-cadherin and plakoglobin expression and higher vimentin and fibronectin (FN1) expression. This cluster also induced ZEB1, ZEB2, SNAIL2, MMP2, and MMP9 and suppressed the expression of breast cancer metastasis suppressor 1-like (BRMS1L), an antimetastatic gene (40) .
Several studies have implicated GH in mammary carcinogenesis in other, non-EMT-related mechanisms. Autocrine/paracrine hGH has been associated with increased vascular endothelial growth factor A expression in MCF7-hGH cells, leading to increased migration and invasion of cocultured HMEC-1 vascular endothelial cells (88) . Other studies have documented an increase in secretion of GH induced by progesterone in mammary epithelial cells, resulting in increased proliferation of stem cells and neovascularization (89, 90) .
GH in colorectal cancer EMT
hGH expression has been associated with increased cell motility and invasion in human colorectal cancer cell lines DLD-1 and Caco2. In these lines, autocrine/ paracrine hGH expression increased expression of mesenchymal markers vimentin and FN1 while decreasing E-cadherin expression. These changes were associated with activation of p44/42 MAPK and could be prevented with the mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor PD98059 or forced E-cadherin expression (41) .
A study performed by Chesnokova et al. (42) in 2016 looked in depth at the ability of exogenous GH to exacerbate the progression of colorectal carcinoma. In this study, human colon cancer cells (HCT116) and nontumorous human colon cells (hNCC) were treated with GH for 24 hours. HCT116 cells exhibited increased SNAIL1, whereas hNCC cells showed dosedependent upregulation of TWIST2 and increased b-catenin nuclear localization. Colon organoids treated with GH also showed decreases in E-cadherin and increases in N-cadherin. This study also noted GH-dependent decreases in p53, p21, and phosphatase and tensin homolog (PTEN) along with increases in the adenomatous polyposis coli oncogene using in vitro and in vivo experiments. Increases in MEK/extracellular signalrelated kinase (ERK) signaling were implicated in the in vitro process. In colorectal carcinoma cell lines, it is worth noting that both autocrine/paracrine GH and exogenous GH resulted in an MEK/ERK-directed EMT process, whereas only the autocrine/paracrine condition stimulated MAPK activity.
GH in pancreatic cancer EMT
A study published in 2014 (43) indicated that enhanced GHR expression in three lines of pancreatic ductal adenocarcinoma (PANC-1, HPAC, and MIAPaCa-2 lines) resulted in increased cell migration via scratch and transwell assays. Silencing the GHR gene resulted in decreased markers of EMT, including N-cadherin, vimentin, NOTCH2, SNAIL, ZEB, and SLUG, as well as increased E-cadherin expression (43) . This study also found that PTEN was activated by GHR repression in a PI3K/AKTdependent manner. To date, the PI3K/AKT pathway has not been attributed to the EMT process by either endocrine or autocrine/paracrine GH in any other cell types.
GH in endometrial EMT
Research has shown elevated hGH expression in endometriosis and endometrial adenocarcinoma (72) . Endometriosis, a condition in which endometrial tissue leaves the uterus and invades other areas of the body, has been correlated with increased markers of EMT in several studies (91) (92) (93) . Although endometriosis is not recognized as a type of cancer, the presence of increased hGH expression suggests a potential role for GH in endometrial EMT. In the human endometrial carcinoma cell line RL95-2, forced hGH expression resulted in cell cycle progression and decreased apoptotic cell death (44) . GH overexpression in these cells increased mRNA levels of mesenchymal markers, including ECM protein FN1, a-catenin, and b-catenin, indicating that EMT is induced by autocrine/paracrine GH in these cells. These cells also demonstrated increased mRNA levels of metastatic genes, including MET proto-oncogene and MMP9. Features of migration and invasion in GH-expressing RL95-2 cells were elevated as well, whereas functional antagonism of hGH with the active component of pegvisomant reduced cell proliferation and growth. Xenograph mouse models using RL95 cells have also shown that pegvisomant reduces cancer regrowth after treatment, suggesting a potential use for the antagonist in preventing relapse of human endometrial cancers (94) .
GH in melanoma EMT
GH and GHR expression in human melanoma cells is one of the highest among all cancers in the NCI-60 panel of cancer cells (95) . Recently, a direct effect of GH on regulation of EMT markers was observed in human melanoma cells, where GH treatment increased RNA and protein levels of N-cadherin and vimentin, whereas E-cadherin levels were suppressed (45) . In contrast, an siRNA-mediated GHR knockdown resulted in reappearance of E-cadherin and marked downregulation of N-cadherin and vimentin levels. Additional reports found increase of RNA levels of EMT markers in vemurafenibresistant melanoma or following GH treatment of human melanoma cells with concomitant increase in vemurafenib half-maximal effective concentration (96) . In vivo verification of these observations can further validate the GH regulation of EMT in human melanoma.
GH-induced EMT in other models

GH-induced EMT in podocytes
The podocyte is a specialized cell in the glomerulus that functions to create the slit diaphragm, a network of intercellular proteins spanning cellular junctions, functioning as a filtration barrier. When the podocyte is injured, the slit diaphragm is compromised, and large proteins, chiefly albumin, are permitted to leave the bloodstream and enter the urine. Podocyte EMT has been well described; however, it is agreed that this instance of EMT is atypical (97, 98) . Mature podocytes express P-cadherin instead of E-cadherin in their adherens junctions. It is generally accepted that P-cadherin is the surrogate marker of EMT in podocytes, as a shift from P-to N-cadherin is associated with the induction of EMT markers after TGF-b treatment (97, 99, 100) .
GH has several known effects on the kidney, including transient increases in glomerular filtration rate and increased expression of sodium channels in the distal nephron, causing increased water uptake (101) (102) (103) (104) . Studies performed in 2001 found a twofold increase in integrin-linked kinase (ILK) mRNA within the glomerulus of bovine GH transgenic mice, a model associated with glomerulosclerosis and progressive kidney disease. Primary culture showed increased ILK specifically occurred in the podocytes of these mice (104) . This finding is important in that ILK, a serine threonine kinase, negatively regulates P-and E-cadherin expression and activates b-catenin (105) . Biopsies of patients with focal segmental glomerulosclerosis have also shown increased ILK, mainly in the podocyte, with decreased podocyte expression of P-cadherin and nuclear b-catenin localization (106) .
A 2010 study by Kumar et al. (107) , working with the laboratory of Menon, identified GH-dependent increases in podocyte ZEB2 that were associated with decreased E-and P-cadherin. ZEB2 binds CACCT sequences to suppress transcription, as is the case with the CACCT sequences found in E-and P-cadherin promoters (108) . This study also found that GH could induce ZEB2-associated decreases in E-cadherin in HepG2 cells, a hepatoma cell line (107) . These researchers later determined that GH action in the podocyte induces secretion of TGF-b-induced protein (TGF-bI), a protein associated with increased podocyte migration (109) . Interestingly, TGF-bI has also been associated with increased colon cancer extravasation and high-grade colon cancers, leading to the speculation that GH may also induce TGF-bI in such colon cancers (110) .
Contrary to most evidence presented in this article, pretreatment of podocytes with 1.25 nM (25 ng/mL) GH has also been associated with a reversal in homocysteine (HCys)-induced EMT. The proposed mechanism by which GH performs this function is by inhibiting NADPH oxidase production, thereby decreasing oxidative stress, as well as rescuing decreases in vascular endothelial growth factor A secretion caused by HCys. More specifically, this study showed that GH inhibits formation of membrane-bound, redox raft signaling platforms, which are necessary to recruit NADPH oxidase (111) . A similar study performed in 2013 (112) supports this protective role of GH, as pretreatment of uninephrectomized mice on a folatefree diet with recombinant mouse GH prevented postsurgical injury known to be associated with increased HCys. Specifically, recombinant mouse GH pretreatment inhibited expression of mesenchymal markers FSP-1 and a-smooth muscle actin while increasing expression of the podocyte-specific marker podocin, encouraging the typical epithelial phenotype (112) .
Conclusion
A strong body of evidence suggests GH plays a role in the progression of certain cancer types through the induction of EMT. Research indicates that the primary role of GH in cancer progression is likely in promoting metastasis, not in the development of new cancer. This role can be carried out through numerous regulatory pathways, including the upregulation of de novo methyltransferases and miRNAs that repress the expression of the epithelial marker plakoglobin, as is the case in breast cancer cells. GH can also increase transcription of key metastasis-related genes, including MMPs, cMYC, BCL-2, and CHOP. JAK2-mediated signaling is implicated in this process, along with other second messengers including STAT5, MEK, and SRC. The end point of this signaling is the downregulation of epithelial markers and the acquisition of mesenchymal markers, enhancing cell motility and invasiveness.
Previous literature also suggests that GH can modulate immune cell infiltration, potentially creating a tumor microenvironment that enhances EMT, a subject requiring more study (113, 114) .
Although GH-induced EMT can occur via endocrine or autocrine/paracrine activity, only breast cancer studies have looked at cell-specific differences between the two. In certain cells, exogenous and autocrine/ paracrine GH may act through different pathways to produce a similar EMT process. For example, MAPK activity was reported to be associated with EMT in colorectal carcinoma and breast cancer cell lines overexpressing GH (autocrine/paracrine), but not in any cancer lines given exogenous GH. More research into the differences between the effects of autocrine/ paracrine and exogenous GH on both cancerous and noncancerous EMT is warranted. A recent review (75) looks more in depth at tumor-derived hGH, as this has interesting therapeutic implications.
When considering the impact of GH-induced EMT on overall disease progression, it is important to understand the contribution of other members in the GH/IGF1 axis on a case-by-case basis. As mentioned previously, IGF1 has its own individual effect on EMT that, like GH, varies from one cell type to another. In somatotroph adenomas, decreased somatostatin receptor expression has also been correlated with increased markers of EMT and increased tumor aggressiveness (115) (116) (117) . Although the GHR is expressed in somatotrophs and does contribute to the autoregulation of GH release and potentially to adenoma formation, current literature suggests that the EMT process in these cells is most closely related to somatostatin receptor expression, not GHR expression (118, 119) . GHRH is also known to contribute to disease by enhancing EMT, as is the case in benign prostatic hyperplasia, in which elevated GHRH activity both in vivo and in vitro increases N-cadherin levels and the hyperplasic phenotype (120) .
Our overall impression is that GH-induced EMT is a process induced in highly plastic cells of the epithelial lineage. It is reasonable to suspect GH may induce EMT in other specialized epithelial cells, such as neuroepithelia, another necessary topic of future research. In cases of GH-induced EMT, other members in the GH/IGF1 axis (e.g., IGF1, GHRH, and somatostatin) may be perturbed and contribute individually to the EMT process. The ability for GH to induce EMT in numerous cell types may provide further explanation for the array of tissue types affected in pathological states of excess GH secretion. This relationship may also help explain the reported procancerous role of GH in invasion and metastasis of certain tumors and the detrimental role of excess GH in other noncancerous diseases.
